Name: SyB V-1901 & SyB L-1701/L-1702
Brand: SymBio Pharma USA, Inc.

Health and Medical

IV Brincidofovir is a novel antiviral medication being developed by SymBio Pharmaceuticals for the treatment of various viral infections, including adenovirus infection following hematopoietic stem cell transplantation and Epstein-Barr virus associated lymphoproliferative disease.  It is currently in clinical trials.

IV Brincidofovir

Pharmaceutical

Manufacturing and Industry

SymBio Pharma USA, Inc.

North Carolina

Biopharma

Manufacturing

These are proprietary drug candidates in various stages of development within SymBio Pharmaceuticals’ pipeline, representing the company’s commitment to innovative therapeutic solutions.

SyB V-1901 & SyB L-1701/L-1702

Other products/services from SymBio Pharma USA, Inc.

IV Brincidofovir

N/A